Stephen W Marcella
Overview
Explore the profile of Stephen W Marcella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
402
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clancy C, Cornely O, Marcella S, Nguyen S, Gozalo L, Cai B
Infect Drug Resist
. 2024 Oct;
17:4427-4443.
PMID: 39431212
Purpose: The international PROVE retrospective chart-review study aims to assess the real-world effectiveness and safety of cefiderocol for treatment of patients with carbapenem-resistant Gram-negative infections. Patients And Methods: US centers...
2.
Doremus C, Marcella S, Cai B, Echols R
Infect Dis Ther
. 2021 Nov;
11(1):187-199.
PMID: 34731456
Introduction: Colistin is used to treat severe antibiotic-resistant Gram-negative infections (GNIs). With the rise of antibiotic resistance, colistin has been used increasingly as a 'last-line' therapy for multidrug-resistant GNIs. We...
3.
Hengel R, Ritter T, Nathan R, Van Anglen L, Schroeder C, Dillon R, et al.
Open Forum Infect Dis
. 2020 May;
7(4):ofaa097.
PMID: 32363211
Background: Bezlotoxumab is approved for prevention of recurrence of infection (CDI) in adults receiving standard of care (SoC) therapy based on findings from MODIFY clinical trials. However, utilization practices and...
4.
Mikamo H, Kondo T, Okuyama K, Marcella S, Ruzicka D
Anaerobe
. 2019 Dec;
61:102139.
PMID: 31830597
This retrospective cohort study aimed to determine the incidence rates of and risk factors for recurrent Clostridioides difficile infection (rCDI) in Japan using a claims database. Inpatients of any age...
5.
Zhang D, Prabhu V, Marcella S
Clin Infect Dis
. 2018 Jan;
66(9):1326-1332.
PMID: 29360950
Background: The economic burden of Clostridium difficile infection (CDI), the leading cause of nosocomial infectious diarrhea, is not well understood. The objective of this study was to estimate the healthcare...
6.
Wilcox M, Ahir H, Coia J, Dodgson A, Hopkins S, Llewelyn M, et al.
J Antimicrob Chemother
. 2017 Jun;
72(9):2647-2656.
PMID: 28633368
Objectives: Data quantifying outcomes of recurrent Clostridium difficile infection (rCDI) are lacking. We sought to determine the UK hospital resource use and health-related quality of life (HRQoL) associated with rCDI...
7.
Chan T, Marcella S, Gill H, Hwang Y, Kwong Y
J Med Econ
. 2015 Sep;
19(1):77-83.
PMID: 26366612
Background: Posaconazole is superior to fluconazole/itraconazole in preventing invasive fungal diseases (IFDs) in neutropenic patients. Whether the higher cost of posaconazole is offset by decreases in IFDs in a given...
8.
Brolin R, Cody R, Marcella S
Surg Obes Relat Dis
. 2015 Jun;
11(6):1201-6.
PMID: 26048522
Background: The Obesity Surgery Mortality Risk Score (OS-MRS) was developed to ascertain preoperative mortality risk of patients having bariatric surgery. To date there has not been a comparison between open...
9.
Sung A, Marcella S, Xie Y
J Med Econ
. 2014 Dec;
18(5):341-8.
PMID: 25524741
Objectives: Posaconazole has shown superior clinical efficacy in the prevention of invasive fungal disease (IFD) among neutropenic patients as well as cost-effectiveness in the US healthcare setting vs fluconazole or...
10.
Rubenstein E, Shendell D, Eggert B, Marcella S
Workplace Health Saf
. 2014 Feb;
62(1):12-8.
PMID: 24571050
Students with special health care needs (SHCNs) and individualized education plans (IEPs) may be injured more often in vocational, career, and technical education (CTE) programs. No research to date considers...